Silk Road Medical announced it has received up to $57 million in equity and debt funding from new and existing investors. CRG, a new investor in Silk Road Medical, led the debt financing and also participated as an equity investor alongside returning investors Warburg Pincus and The Vertical Group.

“The strength of this financing is a testament to the large opportunity we have to solve unmet clinical needs and lead the next endovascular revolution with TCAR,” said Erica Rogers, chief executive officer of Silk Road Medical.

Sunnyvale, CA-based Silk Road Medical is a private company that develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies.